US3717634A - N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones - Google Patents
N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones Download PDFInfo
- Publication number
- US3717634A US3717634A US00879604A US87960469A US3717634A US 3717634 A US3717634 A US 3717634A US 00879604 A US00879604 A US 00879604A US 87960469 A US87960469 A US 87960469A US 3717634 A US3717634 A US 3717634A
- Authority
- US
- United States
- Prior art keywords
- formula
- heteroarcyclic
- compounds
- reaction
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
Definitions
- n is the integer 4 or 5.
- the symbol -A which connects the spiroglutarimide and the N-(heteroarcyolic)piperazine represents a divalent alkylene chain of 2 to 6 carbon atoms inclusive. Said alkylene chain can be straightor branched-chain hydrocarbon grouping in which the ring connecting bonds are on different carbon atoms such as hexamethylene (CH2 CH2 CH2CH CHzCHz) 2-methyl-1,2-propylene OH2C and the like.
- the piperazine substituent represented by the symbol B is selected from the group consisting of imidazoyl and a heteroarcyclic. Said heteroarcyclic is represented by the symbol:
- W and Y are independently selected from th group consisting of CH and nitrogen.
- heteroancyclic as used herein, it is meant substituents comprised of nitrogen, carbon, and hydrogen which when taken together form a heteroaromatic system.
- R and R substituents of the heteroarcyclic referred to above are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 4 carbon atoms inclusive, alkoxy of from 1 to 4 carbon atoms inclusive, hydroxy, amino, alkylthio of 1 to 4 carbon atoms inclusive, halogen, trifiuoromethyl, alkanoamido of from 1 to 6 carbon atoms inclusive, and alkanesulfonamido of 1 to 6 carbon atoms inclusive.
- lower alkyl as employed herein it is meant straight or branched chain alkyl radicals including methyl, ethyl, propyl, isopropyl, l-butyl, l-methylpropyl, Z-methylpropyl, and tert.-butyl.
- alkyl fragment of the alkylthio substituent refers to straight or branched chain radicals described above.
- Straight or the branched chain alkanes of 1 to 6 carbon atoms inclusive comprise the alkane radical of alkanoamido and alkanesulfonamido groupings.
- non-toxic pharmaceutically acceptable acid addition salts refers to a combination of compounds of the present invention with relatively nontoxic inorganic or organic acids.
- acids which may be used are sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, methanesulfonic, benzenesulfonic, para-toluenesulfonic, acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, and related acids.
- Conversion of the compounds of the present invention to pharmaceutically acceptable acid addition salts is accomplished by admixture of these compounds with substantially one chemical equivalent of any of the various acids hereinbefore defined.
- the reactions are carried out in an inert solvent.
- Suitable solvents are ethanol, benzene, ethyl acetate, ether, and halogenated hydrocarbons.
- Method A is carried out by reacting a spiro-substituted glutaric anhydride of Formula II with the l-(w-aminoalkyl) 4 (heteroarcyclic)piperazines of Formula III to provide products of Formula I.
- the reaction is carried out at elevated temperatures in a reaction inert organic solvent.
- inert organic solvent as referred to herein is meant any protic or aprotic solvent or diluent which does not enter into the reaction to any substantial degree.
- Pyridine is the preferred solvent.
- Temperatures of about 100 C. to about 200 C. are preferred to facilitate completion of the reaction.
- the duration of the reaction is critical only to the extent of providing maximum yields and reaction periods of from about 16 hr. to as much as 11 days are preferred. The lengthy reaction periods are necessary in some instances to obtain complete conversion of glutaric acid half-amides of Formula VIII which are initially formed when an anhydride of Formula II is combined with an amine of Formula III.
- the glutaric acid half-amides of Formula VIII may be also transformed into Formula I products by heating in boiling acetic anhydride which is a well known standard organic procedure for ring closure useful in the formation of cyclic imides.
- Method B is carried out under reaction conditions amply described in literature wherein teritary amines are formed by alkylation of a secondary amine with an alkyl halide, sulfate, phosphate, tosylate, or mesylate.
- the Formula IV and Formula V intermediates are preferably reacted in an inert liquid reaction medium at temperatures of from about 60 C. to about 200 C. in the presence of a base suitable for use as an acid binding agent.
- Sodium carbonate is a particularly preferred acid binding agent but other inorganic and tertiary organic base may be employed including other alkali and alkaline earth metal carbonates, bicarbonates, or hydrides and tertiary amines. Reaction periods ranging from about 2 hrs.
- a particularly preferred solvent is n-butanol but any inert reaction medium is generally applicable to use in this reaction.
- the duration of the reaction period depends upon the temperature and reaction solvent selected. By way of illustration, alkylation is facilitated and the reaction period is appreciably shortened if dimethylformamide is employed as the reaction medium compared to a solvent such as benzene.
- Method C is another method useful for preparation of compounds of Formula I.
- the spiroglutarirnide metal salt depicted by Formula VI is reacted with substituted piperazines of Formula VII.
- Standard laboratory procedures are employed in carrying out the reaction such as those described for the alkylation step of the Gabriel synthesis-S. Gabriel, Ber. 20, 2224 (1887).
- the reactants are combined in an inert reaction medium at temperatures ranging from about 25 C. to 200 C.
- Preferred solvents for carrying out the reaction are dimethylformamide, acetone, benzene, n-butanol, ethanol and the like.
- N (heteroarcyclic)piperazines of Formula V have been described by K. L. Howard at al. in J. Org. Chem., 18, 1484 (1953). Their procedures are applicable to the preparation of other N-(heteroarcyclic)piperazine intermediates not specifically disclosed but which are required for the preparation of compounds embraced in the present invention.
- the l-(w-aminoalkyl)-4-(heteroarcyclic)piperazine of Formula III are obtained according to methods described in U.S. Pat. 3,398,151 by alkylation of N- (heteroarcyclic)piperazines of Formula V with haloalkylnitriles to provide 1 (w cyanoalkyl) 4 (heteroarcyclic)piperazine intermediates which are subsequently reduced to the Formula III substituted piperazines.
- Reduction of the cyano intermediate may be carried out catalytically, preferably with W-6 Raney Nickel catalyst under high pressure, or alternatively with hydrazine and W-6 Raney Nickel.
- the intermediate azaspirodecane-and undecanediones of Formula IV having the -A-X- group attached to the nitrogen atom are prepared according to procedures described in U.S. Pat. 3,398,151. Reaction 'of the glutaric anhydrides of Formula II with an alkanolamine of the formula H NAOH are carried out under conditions similar to those described hereinabove for Method A.
- the resulting intermediate .g'lutarimide has the structure shown for Formula IV wherein X is OH. Esterification of this material is accomplished by conventional techniques well known to the art to provide the intermediate of Formula IV.
- Conventional techniques which are adequately described in the literature are employed to provide the bromides, iodides, phosphates, sulfates, tosylates, and mesylates corresponding to Formula IV.
- the piperazine reactant of Formula VII having the X-A- grouping attached to the nitrogen atom is prepared according to standard organic procedures.
- Formula VIII This intermediate is then esterified according to conventional techniques well known to the art to provide the Formula VH reactants. For instance, thionyl chloride acting upon the compounds of Formula VIII provides the Formula VII intermediate in which X is chlorine. In a similar fashion, bromides, and iodides are prepared. Phosphates, sulfates, tosylates, mesylates corresponding to Formula VII are obtained with conventional laboratory techniques.
- azaspiroalkanedione of Formula I are prepared in accordance with the unitary process of the present invention by reacting a piperazine of the Formula Y-bi NB Formula IX wherein Y is selected from the group consisting of hydrogen (Formula IXa), H 'NA- (Formula IXb), or XA-- (Formula IXc), and A and X are as hereinbefore defined, with a spirO-glutaric acid anhydride of Formula II.
- N- (heteroarcyclic)piperazine alkyl derivatives of azaspirodecanediones and azaspiroundecanediones are highly active and specific tranquilizing agents and in addition also exhibit anti-emetic properties.
- Present compounds are improved tranquilizing agents compared to the azaspirodecanediones and azaspiroundecanediones of United States Pat. 3,398,151, in that tranquilizing activity is more potent and specific.
- Tranquilizing properties of the compounds of this invention can be demonstrated in rats by a shuttle box technique described by I. R. Albert and L. E. .Allen in the Ph'armacologist 4, '152 (1962). This test is designed to differentiate tranquilizing agents from non-specific central nervous system depressants such as sedatives and hypnotics. Tranquilizing effects are observed when the compounds of the present invention are administered intraperitoneally to the rat in dosages ranging from 1.5 to mg./kg. of body weight.
- the tranquilizing action of the compounds of the present invention can be demonstrated in Rhesus monkeys by observing general behavioral effects. Intramuscular administration of present compounds to the monkey in dosages ranging from 2 to 16 mg./kg. of body Weight affords tranquilizing effects similar to those produced by chlorpromazine.
- the compounds of the present invention are relatively non-toxic compounds.
- the intraperitoneal 50% lethality dose of 8 [4 [4 (2pyrimidinyl)- 1 piperazinyl1butyl] 8 azaspiro[-4.5]decane-7,9-dione hydrochloride is 146 mg./kg. of body weight in the mouse.
- Systemic administration of the compounds of the present invention to mammals in dosages ranging from about 0.01 to 40 mg./kg. of body weight per day induce effective tranquilizing responses in the mammalian recipient.
- Oral, parenteral and rectal routes are preferred forms of systemic administration.
- Forms of parenteral administration include intramuscular, intravenous, and subcutaneous administration.
- the dosage of the compounds of the present invention will vary with the form and mode of administration and in some instances with the particular compound chosen. Generally, it will be found that when a compound of the present invention is administered orally, a larger quantity of the active agent is required to produce the same effect as a smaller quantity thereof which is given parenterally. It is generally preferred to administer the compounds of this invention at a concentration level that will produce effective tranquilizing effects without causing any harmful or deleterious side effects.
- the compounds of Formula I may be administered to mammals in the form of free bases or in the form of non-toxic acid addition salts.
- the compounds are relatively insoluble in water but are soluble in most organic sol vents such as lower alkyl alcohols, esters, acetones, chloroform and the like.
- the present compounds in the form their acid addition salts are, in general, soluble in water and methanol but relatively insoluble in solvents such as benzene, ether, petroleum ether and the like.
- the compounds of Formula I may be compounded and formulated into pharmaceutical compositions and unit dosage suitable for systemic administration.
- Organic or inorganic Examples of representative compounds of the present invention prepared according to Procedure 1 are indicated in Table I.
- compositions considered within the scope of this invention may take the form of tablets, powder, granules, capsules, suspensions, solutions, suppositories, elixirs, ointments and the like. Unit dosages ranging from about 1 to 500 mg. are employed.
- Suitable pharmaceutical carriers comprise both solids and liquids such as corn starch, lactose, calcium phosphate, stearic acid, polyethylene glycol, water, sesame seed oil, peanut oil, propylene glycol, and the like.
- the azaspiroalkanedione product is purified as the free base by stripping oi the pyridine solvent and crystallizing the residue from a suitable solvent or by vacuum distillation thereof.
- Suitable acid addition salts of the product are prepared by treating an ethanol solution of the free base with an equi-molar amount of the appropriate acid.
- Examples 8-28.Additional exemplification of compounds of the present invention is given in Table II along with the mode of preparation according to Method A, Method B, or Method C and the appropriate intermediates. Although only a single method of preparation TABLE II-Contlnued Product Ex. No. 11 A Het. Method Intermediates 21 4 (CHz)4- O-C(CH;); B 8-(4-ehlorobutyl)-8-azaspir0I4.5]decane-7,9-dlone and l-[2-(4-tert.-butylpyrimidinympiperazine.
- azaspiroalkanedione compounds of the present invention are formulated for parenteral administration according to the following example.
- a sterile solution suitable for intravenous injection is prepared by dissolving 21.9 g. of 8-[4- [4-(2-pyrimidinyl) 1 piperazinyl]butyl] 8 azaspiro[4.5]decane-7,9-dione hydrochloride in 2 liters of water for injection, USP.
- the solution is adjusted to pH 4.2 with 0.1 N-sodium hydroxide.
- the solution is sterilized by passage through a bacteriological filter and ml. glass ampules aseptically filled in order to provide 10 mg. of active ingredient per ampule.
- n is the integer 4 or 5;
- A is a divalent straight or branched alkylene chain of 2 to 6 carbon atoms inclusive and connects the nitrogen atoms as shown through at least 2 carbon atoms;
- R and R are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 4 carbon atoms inclusive, and lower alkoxy of from 1 to 4 carbon atoms inclusive;
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE759371D BE759371A (fr) | 1969-11-24 | Azaspirodecanediones heterocycliques et procedes pour leur preparation | |
US00879604A US3717634A (en) | 1969-11-24 | 1969-11-24 | N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones |
ZA707826A ZA707826B (en) | 1969-11-24 | 1970-11-19 | Heterocyclic azaspirodecanediones and process for the preparation thereof |
FR7041860A FR2073406B1 (xx) | 1969-11-24 | 1970-11-20 | |
DK589670AA DK141753B (da) | 1969-11-24 | 1970-11-20 | Analogifremgangsmåde til fremstilling af azaspirodecan- og -undecandionderivater eller syreadditionssalte deraf. |
NL7017031A NL7017031A (xx) | 1969-11-24 | 1970-11-20 | |
DE19702057845 DE2057845A1 (de) | 1969-11-24 | 1970-11-24 | Heterocyclische Azaspirodecandione und Verfahren zu ihrer Herstellung |
GB5590870A GB1332194A (en) | 1969-11-24 | 1970-11-24 | Heterocyclic azaspiroalkanediones |
CH341874A CH552608A (de) | 1969-11-24 | 1970-11-24 | Verfahren zur herstellung von azaspiroalkandion-derivaten. |
CY886A CY886A (en) | 1969-11-24 | 1970-11-24 | Heterocyclic azaspiroalkanediones |
CH1741770A CH552607A (de) | 1969-11-24 | 1970-11-24 | Verfahren zur herstellung von azaspiroalkandion-derivaten. |
US312543A US3907801A (en) | 1969-11-24 | 1972-12-06 | N-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones |
KE2691A KE2691A (en) | 1969-11-24 | 1977-01-14 | Heterocyclic azaspiroalkanediones |
HK61/77A HK6177A (en) | 1969-11-24 | 1977-01-27 | Heterocyclic azaspiroalkanediones |
MY151/77A MY7700151A (en) | 1969-11-24 | 1977-12-30 | Heterocyclic azaspiroalkane diones |
ES530335A ES530335A0 (es) | 1969-11-24 | 1984-03-07 | Procedimiento para la obtencion del clorhidrato de 8-4-4-(2-pirimidinil)-1-piperazinil-butil-8-azaspiro 4,5-decano-7,9- diona. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00879604A US3717634A (en) | 1969-11-24 | 1969-11-24 | N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US312543A Division US3907801A (en) | 1969-11-24 | 1972-12-06 | N-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones |
Publications (1)
Publication Number | Publication Date |
---|---|
US3717634A true US3717634A (en) | 1973-02-20 |
Family
ID=25374483
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00879604A Expired - Lifetime US3717634A (en) | 1969-11-24 | 1969-11-24 | N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones |
US312543A Expired - Lifetime US3907801A (en) | 1969-11-24 | 1972-12-06 | N-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US312543A Expired - Lifetime US3907801A (en) | 1969-11-24 | 1972-12-06 | N-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones |
Country Status (14)
Country | Link |
---|---|
US (2) | US3717634A (xx) |
BE (1) | BE759371A (xx) |
CH (2) | CH552607A (xx) |
CY (1) | CY886A (xx) |
DE (1) | DE2057845A1 (xx) |
DK (1) | DK141753B (xx) |
ES (1) | ES530335A0 (xx) |
FR (1) | FR2073406B1 (xx) |
GB (1) | GB1332194A (xx) |
HK (1) | HK6177A (xx) |
KE (1) | KE2691A (xx) |
MY (1) | MY7700151A (xx) |
NL (1) | NL7017031A (xx) |
ZA (1) | ZA707826B (xx) |
Cited By (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3907801A (en) * | 1969-11-24 | 1975-09-23 | Mead Johnson & Co | N-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones |
US4123538A (en) * | 1977-08-30 | 1978-10-31 | Mcneil Laboratories, Incorporated | (2-Amino-2-oxoethoxy)acetic acid compounds, compositions and methods |
DE2920739A1 (de) * | 1978-05-22 | 1979-12-06 | Bristol Myers Co | Verwendung von 8-eckige klammer auf 4-eckige klammer auf 4-(2-pyrimidinyl)-1piperazinyl eckige klammer zu -butyl eckige klammer zu -8-azaspiro eckige klammer auf 4.5 eckige klammer zu decan-7,9-dion |
US4305944A (en) * | 1980-09-08 | 1981-12-15 | Mead Johnson & Company | N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones |
US4320131A (en) * | 1981-03-16 | 1982-03-16 | Mead Johnson & Company | N-[(4-Phenyl-1,2,3,6-tetrahydropyridin-1-yl)alkylene]azaspiroalkanediones and N-[(4-hydroxy-4-phenylpiperidin-1-yl)alkylene]azaspiroalkanediones |
FR2492383A1 (fr) * | 1980-10-16 | 1982-04-23 | Bristol Myers Co | Halogenures d'ammonium spiro-quaternaire, leur procede de prepatation et leur utilisation dans un procede de production de n-(2-pyrimidinyl) piperazinyl-alkylazospiro-alcanediones |
DE3149011A1 (de) * | 1980-12-11 | 1982-07-15 | Bristol-Myers Co., 10022 New York, N.Y. | Verfahren zur herstellung von buspiron |
US4361565A (en) * | 1981-12-28 | 1982-11-30 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines |
US4367335A (en) * | 1981-08-03 | 1983-01-04 | Mead Johnson & Company | Thiazolidinylalkylene piperazine derivatives |
FR2518993A1 (fr) * | 1981-12-28 | 1983-07-01 | Bristol Myers Co | 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique |
FR2521561A1 (fr) * | 1981-12-23 | 1983-08-19 | Bristol Myers Co | Derives de benzisothiazole et benzisoxale piperazine |
US4409223A (en) * | 1982-08-06 | 1983-10-11 | Riblet Leslie A | Anxiolytic method |
US4417049A (en) * | 1980-10-16 | 1983-11-22 | Mead Johnson & Company | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process |
WO1984000752A1 (en) * | 1982-08-11 | 1984-03-01 | Eastman Kodak Co | Acid salts of 1-(cyanoalkyl)-4-guanylpiperazines and methods for their preparation and use |
US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
US4452799A (en) * | 1981-12-23 | 1984-06-05 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
US4456756A (en) * | 1981-08-03 | 1984-06-26 | Mead Johnson & Company | Spirothiazolidinyl piperazine derivatives |
FR2540499A1 (fr) * | 1983-02-07 | 1984-08-10 | Bristol Myers Co | Derive de 5-fluoro-pyrimidine-2-yl piperazine antipsychotique |
US4507303A (en) * | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
US4515947A (en) * | 1982-08-11 | 1985-05-07 | Eastman Kodak Company | Cyanoalkylpiperazines and methods for their preparation and use |
FR2555585A1 (fr) * | 1983-09-12 | 1985-05-31 | Bristol Myers Co | Derives de la 1-heteroaryl-4 ((2,5-pyrrolidinedion-1-yl) alkyl )piperazine, leur procede de preparation et leur application pharmacologique |
US4562255A (en) * | 1984-03-30 | 1985-12-31 | American Home Products Corporation | Substituted bi-alicyclic imides |
FR2567886A1 (fr) * | 1984-07-23 | 1986-01-24 | Bristol Myers Co | Derives 1-(2-pyrimidinyl)-piperazinyliques de 1-pyrrolidine-2-ones et leur application psychogeriatrique |
US4581357A (en) * | 1983-02-07 | 1986-04-08 | Mead Johnson & Company | Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound |
US4598078A (en) * | 1982-10-21 | 1986-07-01 | Sumitomo Chemical Company, Limited | N-(substituted piperazinyl) alkylbicyclic succinimide derivatives |
US4612312A (en) * | 1984-07-30 | 1986-09-16 | Merrell Dow Pharmaceuticals Inc. | Glutarimide antianxiety and antihypertensive agents |
US4620002A (en) * | 1982-08-11 | 1986-10-28 | Eastman Kodak Company | 2-pyrimidyl alkanesulfonates |
US4619930A (en) * | 1985-01-16 | 1986-10-28 | Bristol-Myers Company | Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use |
US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
DE3622842A1 (de) * | 1985-07-08 | 1987-03-05 | Bristol Myers Co | Diazinylpiperidin-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel |
FR2587342A1 (fr) * | 1985-06-22 | 1987-03-20 | Sandoz Sa | Nouveaux derives du thiazole, leur preparation et leur utilisation en therapeutique |
US4668687A (en) * | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
US4677104A (en) * | 1985-05-06 | 1987-06-30 | Bristol-Myers Company | Antipsychotic fused-ring pyridinylpiperazine derivatives |
US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
EP0236931A2 (en) * | 1986-03-05 | 1987-09-16 | Merrell Dow Pharmaceuticals Inc. | Aromatic omega-alkylimino-tetrahydro-6H-1,3-Thiazin-6-one derivatives |
EP0238905A2 (en) * | 1986-03-05 | 1987-09-30 | Merrell Dow Pharmaceuticals Inc. | 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives |
US4745117A (en) * | 1985-03-27 | 1988-05-17 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives and compositions for use as antipsychotic agents |
US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
EP0304941A1 (en) * | 1987-08-28 | 1989-03-01 | Bristol-Myers Squibb Company | Pharmaceutically useful polymorphic modification of buspirone |
US4810789A (en) * | 1987-08-28 | 1989-03-07 | Bristol-Myers Company | Process for buspirone hydrochloride polymorphic crystalline form conversion |
US4812567A (en) * | 1985-10-16 | 1989-03-14 | American Home Products Corporation | Polycyclic spiroimides with psychotropic activity |
US4812461A (en) * | 1986-09-26 | 1989-03-14 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives and their use in the treatment psychosis |
EP0313535A1 (en) * | 1987-10-22 | 1989-04-26 | Bristol-Myers Squibb Company | Oral formulation of buspirone and salts thereof |
US4826843A (en) * | 1985-07-08 | 1989-05-02 | Bristol-Myers | Cerebral function enhancing diazinylpiperidine derivatives |
EP0314363A2 (en) * | 1987-10-26 | 1989-05-03 | Pfizer Inc. | Anti-anxiety agents |
US4859671A (en) * | 1988-07-08 | 1989-08-22 | American Home Products Corporation | 2-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxide useful as an anxiolytic agent |
US4880930A (en) * | 1987-11-30 | 1989-11-14 | New James S | Psychotropic acyclic amide derivatives |
WO1990002552A1 (en) * | 1988-09-16 | 1990-03-22 | Pfizer Inc. | Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides |
EP0395192A2 (de) * | 1989-04-28 | 1990-10-31 | Alkaloida Vegyeszeti Gyar | Verfahren zur Herstellung von 8-(4-(4-Pyrimidin-2-yl-Piperazinyl)-Butyl)-8-Asaspiro(4.5)Dekan-7,9-Dion (Buspiron) |
US5001130A (en) * | 1988-02-18 | 1991-03-19 | Bristol-Myers Company | Psychotropic heterobicycloalkylpiperazine derivatives |
EP0447345A2 (en) * | 1990-02-13 | 1991-09-18 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | New Azaspyro [4.5] decane-7,9-dione derivatives |
US5098904A (en) * | 1990-06-27 | 1992-03-24 | Bristol-Myers Squibb Company | Cerebral function enhancing pyrimidinyl derivatives |
US5116970A (en) * | 1988-02-18 | 1992-05-26 | New James S | Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones |
US5137894A (en) * | 1991-12-05 | 1992-08-11 | New James S | 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides |
US5153206A (en) * | 1988-12-02 | 1992-10-06 | Pfizer Inc. | Arylpiperidine derivatives |
US5187277A (en) * | 1990-10-29 | 1993-02-16 | Komissarov Igor V | DL-3-[4-[4-(2-pyridyl)-1-piperazinyl]-butyl]-1,8,8-trimethyl-3-azabicyclo[(3]octane-2,4-dione having psychotropic and antiemetic effect |
US5242911A (en) * | 1988-06-17 | 1993-09-07 | Pfizer Inc. | Bridged bicyclic imides as anxiolytics and antidepressants |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
US5391570A (en) * | 1993-10-14 | 1995-02-21 | Bristol-Myers Squibb | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
US5407938A (en) * | 1990-04-10 | 1995-04-18 | Israel Institute For Biological Research | Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines) |
EP0655449A1 (en) * | 1993-11-10 | 1995-05-31 | Jin Ro Limited | A process for preparing N-( 2-pyrimidyl) piperazinyl butyl imides |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
WO1996006846A1 (es) * | 1994-09-01 | 1996-03-07 | Universidad Complutense De Madrid | Nuevos derivados de arilpiperazinas |
ES2082727A1 (es) * | 1994-09-01 | 1996-03-16 | Univ Madrid Complutense | Nuevos derivados de arilpiperazinas. |
US5521313A (en) * | 1994-05-05 | 1996-05-28 | Bristol-Myers Squibb Company | Process for preparing certain azapirones |
US5538985A (en) * | 1994-01-27 | 1996-07-23 | Mitsui Toatsu Chemicals, Inc. | Pyrrolidinone derivatives |
US5602128A (en) * | 1994-12-02 | 1997-02-11 | American Home Products Corporation | N-heterocycloalkyl carboxamides as serotonergic agents |
ES2095811A1 (es) * | 1995-07-28 | 1997-02-16 | Univ Madrid Complutense | Nuevos derivados de arilpiperazinas. |
US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
US5852029A (en) * | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
US6008222A (en) * | 1996-12-04 | 1999-12-28 | Bristol-Myers Squibb Company | Method for oral administration of buspirone and nefazodone |
WO2000006163A1 (en) * | 1998-07-30 | 2000-02-10 | Bristol-Myers Squibb Company | Improved method for treatment of sleep-related respiratory disorders |
US6037360A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
US6150365A (en) * | 1999-08-05 | 2000-11-21 | Bristol-Myers Squibb Company | Anxiety method |
US6228864B1 (en) | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
US6306859B1 (en) | 1999-03-02 | 2001-10-23 | American Home Products Corporation | N-substituted imide derivatives with serotonergic activity |
US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
US6313114B1 (en) | 1999-01-07 | 2001-11-06 | American Home Products Corp | 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]- amines |
US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
US20030069251A1 (en) * | 1999-08-05 | 2003-04-10 | Yevich Joseph P. | Antianxiety composition |
US6566361B2 (en) | 1999-06-30 | 2003-05-20 | Laboratories, Upsa | Azapirone pain treatment |
US20040067962A1 (en) * | 2000-11-29 | 2004-04-08 | Schaus John Mehnert | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof |
US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
US6828324B2 (en) | 1999-11-12 | 2004-12-07 | Wyeth | Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT1A activity |
US6831084B1 (en) | 1999-11-12 | 2004-12-14 | Wyeth | Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity |
US20050107395A1 (en) * | 2002-09-05 | 2005-05-19 | Greenblatt Lynne P. | Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents |
US20050137206A1 (en) * | 1999-08-05 | 2005-06-23 | Yevich Joseph P. | Method for treatment of anxiety and depression |
US20050272799A1 (en) * | 2000-09-19 | 2005-12-08 | Salvati Mark E | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
WO2006108591A1 (en) | 2005-04-11 | 2006-10-19 | Novartis Ag | 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands |
US20090023744A1 (en) * | 2007-06-18 | 2009-01-22 | The General Hospital Corporation | Combination therapy for depression |
US20100184775A1 (en) * | 2005-12-16 | 2010-07-22 | Novartis Ag | Organic compounds |
US20110034475A1 (en) * | 2004-06-18 | 2011-02-10 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
EP2361914A1 (en) | 2005-12-16 | 2011-08-31 | Novartis AG | [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders. |
WO2012037634A1 (en) | 2010-09-24 | 2012-03-29 | Aché Laboratórios Farmacêuticos S.A. | Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors |
EP2457911A1 (en) | 2004-07-14 | 2012-05-30 | Novartis AG | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. |
US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
US9186359B2 (en) | 2010-10-15 | 2015-11-17 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
US10561618B2 (en) | 2012-04-18 | 2020-02-18 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
US11975104B2 (en) | 2016-07-11 | 2024-05-07 | Contera Pharma A/S | Pulsatile drug delivery system for treating morning akinesia |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
US4656173A (en) * | 1985-04-24 | 1987-04-07 | Bristol-Myers Company | Antipsychotic benzisothiazole S-oxide compound |
PL152958B1 (en) * | 1987-02-25 | 1991-02-28 | Egyt Gyogyszervegyeszeti Gyar | Method for manufacturing piperazine derivatives |
US4797488A (en) * | 1987-04-03 | 1989-01-10 | American Home Products Corporation | Psychotropic polycyclic imides |
US4748240A (en) * | 1987-04-03 | 1988-05-31 | American Home Products Corporation | Psychotropic bicyclic imides |
US4732983A (en) * | 1987-04-03 | 1988-03-22 | American Home Products Corporation | Pyschotropic polycyclic imides |
US4963557A (en) * | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
US4873331A (en) * | 1988-12-09 | 1989-10-10 | American Home Products Corporation | Noradamantyl-carboxylic acid piperazinoalkyl esters |
US4882432A (en) * | 1989-01-09 | 1989-11-21 | American Home Products Corporation | Polycyclic-carbamic acid piperazinoalkyl esters and amides |
GB8909209D0 (en) * | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5340812A (en) * | 1989-04-22 | 1994-08-23 | John Wyeth & Brother, Limited | Piperazine derivatives |
US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
FR2654934B1 (fr) * | 1989-11-29 | 1994-09-30 | Midy Spa | Utilisation de derive [4-(2-pyrimidinyl)-1-piperazinyl] butyliques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
DE69116302T2 (de) * | 1990-10-23 | 1996-05-30 | Akzo Nobel Nv | 4-[4- oder 6-(Trifluormethyl-2-pyridinyl)]-1-piperazinyl-alkyl substituierte Laktame |
US5591748A (en) * | 1991-06-07 | 1997-01-07 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
US5693645A (en) * | 1992-12-23 | 1997-12-02 | Beth Israel Deaconess Medical Center, Inc. | Use of spiperone or spiperone derivatives as immunosuppressant agents |
ATE241359T1 (de) * | 1993-03-26 | 2003-06-15 | Beth Israel Hospital | Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind |
HU217129B (hu) * | 1993-07-16 | 1999-11-29 | EGIS Gyógyszergyár Rt. | Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására |
US20080217501A1 (en) * | 2007-02-14 | 2008-09-11 | Chad Jensen | Power a-frame |
TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
JP5439377B2 (ja) * | 2007-09-14 | 2014-03-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh4受容体のチエノ−及びフロ−ピリミジン調節物質 |
PE20110061A1 (es) | 2008-06-12 | 2011-01-31 | Janssen Pharmaceutica Nv | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL143925C (xx) * | 1965-03-09 | |||
US3398151A (en) * | 1966-02-01 | 1968-08-20 | Mead Johnson & Co | Azaspirodecanediones and azaspiroundecanediones |
BE759371A (fr) * | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
-
0
- BE BE759371D patent/BE759371A/xx not_active IP Right Cessation
-
1969
- 1969-11-24 US US00879604A patent/US3717634A/en not_active Expired - Lifetime
-
1970
- 1970-11-19 ZA ZA707826A patent/ZA707826B/xx unknown
- 1970-11-20 DK DK589670AA patent/DK141753B/da not_active IP Right Cessation
- 1970-11-20 FR FR7041860A patent/FR2073406B1/fr not_active Expired
- 1970-11-20 NL NL7017031A patent/NL7017031A/xx unknown
- 1970-11-24 CY CY886A patent/CY886A/xx unknown
- 1970-11-24 GB GB5590870A patent/GB1332194A/en not_active Expired
- 1970-11-24 DE DE19702057845 patent/DE2057845A1/de active Pending
- 1970-11-24 CH CH1741770A patent/CH552607A/xx not_active IP Right Cessation
- 1970-11-24 CH CH341874A patent/CH552608A/xx not_active IP Right Cessation
-
1972
- 1972-12-06 US US312543A patent/US3907801A/en not_active Expired - Lifetime
-
1977
- 1977-01-14 KE KE2691A patent/KE2691A/xx unknown
- 1977-01-27 HK HK61/77A patent/HK6177A/xx unknown
- 1977-12-30 MY MY151/77A patent/MY7700151A/xx unknown
-
1984
- 1984-03-07 ES ES530335A patent/ES530335A0/es active Granted
Cited By (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3907801A (en) * | 1969-11-24 | 1975-09-23 | Mead Johnson & Co | N-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones |
US4123538A (en) * | 1977-08-30 | 1978-10-31 | Mcneil Laboratories, Incorporated | (2-Amino-2-oxoethoxy)acetic acid compounds, compositions and methods |
DE2920739C2 (xx) * | 1978-05-22 | 1991-08-08 | Bristol-Myers Squibb Co. (N.D.Ges.D.Staates Delaware), New York, N.Y., Us | |
DE2920739A1 (de) * | 1978-05-22 | 1979-12-06 | Bristol Myers Co | Verwendung von 8-eckige klammer auf 4-eckige klammer auf 4-(2-pyrimidinyl)-1piperazinyl eckige klammer zu -butyl eckige klammer zu -8-azaspiro eckige klammer auf 4.5 eckige klammer zu decan-7,9-dion |
US4182763A (en) * | 1978-05-22 | 1980-01-08 | Mead Johnson & Company | Buspirone anti-anxiety method |
US4305944A (en) * | 1980-09-08 | 1981-12-15 | Mead Johnson & Company | N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones |
FR2489823A1 (fr) * | 1980-09-08 | 1982-03-12 | Bristol Myers Co | Nouvelles n-((4-(3-pyridyle substitue en position 3)-piperazino)alkyl)azaspirodecanediones, leur procede de preparation et medicament les contenant |
FR2492383A1 (fr) * | 1980-10-16 | 1982-04-23 | Bristol Myers Co | Halogenures d'ammonium spiro-quaternaire, leur procede de prepatation et leur utilisation dans un procede de production de n-(2-pyrimidinyl) piperazinyl-alkylazospiro-alcanediones |
NL8104660A (nl) * | 1980-10-16 | 1982-05-17 | Bristol Myers Co | Spiro-kwaternaire ammoniumhalogeniden en n-(2-pyrimidinyl)piperazinylalkylazapiroalkaandion-proces. |
US4417049A (en) * | 1980-10-16 | 1983-11-22 | Mead Johnson & Company | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process |
DE3141256A1 (de) * | 1980-10-16 | 1982-08-19 | Bristol-Myers Co., 10022 New York, N.Y. | Spiro-quaternaere ammoniumhalogenide und n-(2-pyrimidinyl)-piperazinylalkylazaspiroalkandion-verfahren |
US4351939A (en) * | 1980-10-16 | 1982-09-28 | Mead Johnson & Company | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process |
DE3149011A1 (de) * | 1980-12-11 | 1982-07-15 | Bristol-Myers Co., 10022 New York, N.Y. | Verfahren zur herstellung von buspiron |
AT380686B (de) * | 1980-12-11 | 1986-06-25 | Bristol Myers Co | Verfahren zur herstellung von buspiron |
US4320131A (en) * | 1981-03-16 | 1982-03-16 | Mead Johnson & Company | N-[(4-Phenyl-1,2,3,6-tetrahydropyridin-1-yl)alkylene]azaspiroalkanediones and N-[(4-hydroxy-4-phenylpiperidin-1-yl)alkylene]azaspiroalkanediones |
FR2510572A1 (fr) * | 1981-08-03 | 1983-02-04 | Bristol Myers Co | Nouvelles thiazolidinediones, leur procede de production et preparation pharmaceutique les contenant |
US4456756A (en) * | 1981-08-03 | 1984-06-26 | Mead Johnson & Company | Spirothiazolidinyl piperazine derivatives |
US4367335A (en) * | 1981-08-03 | 1983-01-04 | Mead Johnson & Company | Thiazolidinylalkylene piperazine derivatives |
US4507303A (en) * | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
US4543355A (en) * | 1981-12-22 | 1985-09-24 | Sumitomo Chemical Company, Limited | Substituted succinimides, compositions and method of use |
FR2521561A1 (fr) * | 1981-12-23 | 1983-08-19 | Bristol Myers Co | Derives de benzisothiazole et benzisoxale piperazine |
US4411901A (en) * | 1981-12-23 | 1983-10-25 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
US4452799A (en) * | 1981-12-23 | 1984-06-05 | Mead Johnson & Company | Benzisothiazole and benzisoxazole piperazine derivatives |
FR2518994A1 (fr) * | 1981-12-28 | 1983-07-01 | Bristol Myers Co | 2-(4-(4,4-dialkyl-2,6-piperidinedion-1-yl) butyl)-1-pyperazinyl) pyridines et leur application pharmacologique |
US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
FR2518993A1 (fr) * | 1981-12-28 | 1983-07-01 | Bristol Myers Co | 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl))-1-piperazinyl) pyrimidines, leur preparation et leur application pharmacologique |
DE3248160A1 (de) * | 1981-12-28 | 1983-07-07 | Bristol-Myers Co., 10154 New York, N.Y. | 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)-butyl)-1-piperazinyl)pyrimidine, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten |
US4361565A (en) * | 1981-12-28 | 1982-11-30 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines |
DE3248138A1 (de) * | 1981-12-28 | 1983-07-07 | Bristol-Myers Co., 10154 New York, N.Y. | 2-(4-(4,4-dialkyl-2,6-piperidindion-1-yl)butyl)-1-piperazinyl)pyridine, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten |
US4409223A (en) * | 1982-08-06 | 1983-10-11 | Riblet Leslie A | Anxiolytic method |
US4620006A (en) * | 1982-08-11 | 1986-10-28 | Eastman Kodak Company | Acid salts of 1-(cyanoalkyl)-4-guanylpiperazines |
US4515947A (en) * | 1982-08-11 | 1985-05-07 | Eastman Kodak Company | Cyanoalkylpiperazines and methods for their preparation and use |
WO1984000752A1 (en) * | 1982-08-11 | 1984-03-01 | Eastman Kodak Co | Acid salts of 1-(cyanoalkyl)-4-guanylpiperazines and methods for their preparation and use |
US4620002A (en) * | 1982-08-11 | 1986-10-28 | Eastman Kodak Company | 2-pyrimidyl alkanesulfonates |
US4598078A (en) * | 1982-10-21 | 1986-07-01 | Sumitomo Chemical Company, Limited | N-(substituted piperazinyl) alkylbicyclic succinimide derivatives |
US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
US4581357A (en) * | 1983-02-07 | 1986-04-08 | Mead Johnson & Company | Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound |
FR2540499A1 (fr) * | 1983-02-07 | 1984-08-10 | Bristol Myers Co | Derive de 5-fluoro-pyrimidine-2-yl piperazine antipsychotique |
JPS59148780A (ja) * | 1983-02-07 | 1984-08-25 | ブリストル―マイヤーズ スクイブ カンパニー | 精神病治療性5−フルオロ−ピリミジン−2−イルピペラジン化合物 |
JPH0319233B2 (xx) * | 1983-02-07 | 1991-03-14 | Burisutoru Maiyaazu Sukuibu Co | |
FR2555585A1 (fr) * | 1983-09-12 | 1985-05-31 | Bristol Myers Co | Derives de la 1-heteroaryl-4 ((2,5-pyrrolidinedion-1-yl) alkyl )piperazine, leur procede de preparation et leur application pharmacologique |
US4524206A (en) * | 1983-09-12 | 1985-06-18 | Mead Johnson & Company | 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives |
US4562255A (en) * | 1984-03-30 | 1985-12-31 | American Home Products Corporation | Substituted bi-alicyclic imides |
US4668687A (en) * | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
FR2567886A1 (fr) * | 1984-07-23 | 1986-01-24 | Bristol Myers Co | Derives 1-(2-pyrimidinyl)-piperazinyliques de 1-pyrrolidine-2-ones et leur application psychogeriatrique |
US4612312A (en) * | 1984-07-30 | 1986-09-16 | Merrell Dow Pharmaceuticals Inc. | Glutarimide antianxiety and antihypertensive agents |
US4619930A (en) * | 1985-01-16 | 1986-10-28 | Bristol-Myers Company | Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use |
US4745117A (en) * | 1985-03-27 | 1988-05-17 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives and compositions for use as antipsychotic agents |
US4677104A (en) * | 1985-05-06 | 1987-06-30 | Bristol-Myers Company | Antipsychotic fused-ring pyridinylpiperazine derivatives |
FR2587342A1 (fr) * | 1985-06-22 | 1987-03-20 | Sandoz Sa | Nouveaux derives du thiazole, leur preparation et leur utilisation en therapeutique |
US4892879A (en) * | 1985-06-22 | 1990-01-09 | Sandoz Pharm. Corp. | 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and tetrahydro-pyridines useful as anxioltic, psychogeriatric, antisepressant and antischiziphrenic agents |
US4737500A (en) * | 1985-06-22 | 1988-04-12 | Sandoz Pharm. Corp. | 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and -tetrahydropyridines useful as anxiolytic, psychogeriatric, antidepressant and antischizophrenic agents |
DE3622842A1 (de) * | 1985-07-08 | 1987-03-05 | Bristol Myers Co | Diazinylpiperidin-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel |
US4826843A (en) * | 1985-07-08 | 1989-05-02 | Bristol-Myers | Cerebral function enhancing diazinylpiperidine derivatives |
US4812567A (en) * | 1985-10-16 | 1989-03-14 | American Home Products Corporation | Polycyclic spiroimides with psychotropic activity |
US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
WO1987004621A1 (en) * | 1986-02-04 | 1987-08-13 | Ekkehard Othmer | Treatment of sexual dysfunction with buspirone |
EP0236931A3 (en) * | 1986-03-05 | 1990-01-17 | Merrell Dow Pharmaceuticals Inc. | Aromatic omega-alkylimino-tetrahydro-6h-1,3-thiazin-6-one derivatives |
EP0238905A2 (en) * | 1986-03-05 | 1987-09-30 | Merrell Dow Pharmaceuticals Inc. | 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives |
EP0236931A2 (en) * | 1986-03-05 | 1987-09-16 | Merrell Dow Pharmaceuticals Inc. | Aromatic omega-alkylimino-tetrahydro-6H-1,3-Thiazin-6-one derivatives |
EP0238905A3 (en) * | 1986-03-05 | 1989-08-09 | Merrell Dow Pharmaceuticals Inc. | 4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives |
US4812461A (en) * | 1986-09-26 | 1989-03-14 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives and their use in the treatment psychosis |
US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
EP0304941A1 (en) * | 1987-08-28 | 1989-03-01 | Bristol-Myers Squibb Company | Pharmaceutically useful polymorphic modification of buspirone |
US5015646A (en) * | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
US4810789A (en) * | 1987-08-28 | 1989-03-07 | Bristol-Myers Company | Process for buspirone hydrochloride polymorphic crystalline form conversion |
EP0313535A1 (en) * | 1987-10-22 | 1989-04-26 | Bristol-Myers Squibb Company | Oral formulation of buspirone and salts thereof |
JP2674170B2 (ja) | 1987-10-22 | 1997-11-12 | ブリストル−マイアーズ・スクウイブ・カンパニー | ブスピロンおよびその塩の経口投与用組成物並びにその製造方法 |
JPH02501744A (ja) * | 1987-10-22 | 1990-06-14 | ブリストル―マイアーズ・スクウイブ・カンパニー | ブスピロンおよびその塩の経口投与用組成物 |
WO1989003676A1 (en) * | 1987-10-22 | 1989-05-05 | Aktiebolaget Astra | Oral formulation of buspirone and salts thereof |
AU604585B2 (en) * | 1987-10-22 | 1990-12-20 | Bristol-Myers Squibb Company | Oral formulation of buspirone and salts thereof |
EP0314363A2 (en) * | 1987-10-26 | 1989-05-03 | Pfizer Inc. | Anti-anxiety agents |
EP0314363A3 (en) * | 1987-10-26 | 1990-07-11 | Pfizer Inc. | Anti-anxiety agents |
US4880930A (en) * | 1987-11-30 | 1989-11-14 | New James S | Psychotropic acyclic amide derivatives |
US5116970A (en) * | 1988-02-18 | 1992-05-26 | New James S | Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones |
US5001130A (en) * | 1988-02-18 | 1991-03-19 | Bristol-Myers Company | Psychotropic heterobicycloalkylpiperazine derivatives |
US5242911A (en) * | 1988-06-17 | 1993-09-07 | Pfizer Inc. | Bridged bicyclic imides as anxiolytics and antidepressants |
US4859671A (en) * | 1988-07-08 | 1989-08-22 | American Home Products Corporation | 2-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxide useful as an anxiolytic agent |
US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
US5077295A (en) * | 1988-09-16 | 1991-12-31 | Pfizer Inc. | Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides |
WO1990002552A1 (en) * | 1988-09-16 | 1990-03-22 | Pfizer Inc. | Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides |
US5153206A (en) * | 1988-12-02 | 1992-10-06 | Pfizer Inc. | Arylpiperidine derivatives |
EP0395192A2 (de) * | 1989-04-28 | 1990-10-31 | Alkaloida Vegyeszeti Gyar | Verfahren zur Herstellung von 8-(4-(4-Pyrimidin-2-yl-Piperazinyl)-Butyl)-8-Asaspiro(4.5)Dekan-7,9-Dion (Buspiron) |
EP0395192A3 (de) * | 1989-04-28 | 1991-05-02 | Alkaloida Vegyeszeti Gyar | Verfahren zur Herstellung von 8-(4-(4-Pyrimidin-2-yl-Piperazinyl)-Butyl)-8-Asaspiro(4.5)Dekan-7,9-Dion (Buspiron) |
US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
EP0447345A3 (en) * | 1990-02-13 | 1992-04-15 | Espanola Prod Quimicos | New azaspyro (4.5) decane-7,9-dione derivatives |
EP0447345A2 (en) * | 1990-02-13 | 1991-09-18 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | New Azaspyro [4.5] decane-7,9-dione derivatives |
US5852029A (en) * | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
US5407938A (en) * | 1990-04-10 | 1995-04-18 | Israel Institute For Biological Research | Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines) |
US5098904A (en) * | 1990-06-27 | 1992-03-24 | Bristol-Myers Squibb Company | Cerebral function enhancing pyrimidinyl derivatives |
US5187277A (en) * | 1990-10-29 | 1993-02-16 | Komissarov Igor V | DL-3-[4-[4-(2-pyridyl)-1-piperazinyl]-butyl]-1,8,8-trimethyl-3-azabicyclo[(3]octane-2,4-dione having psychotropic and antiemetic effect |
US5837280A (en) * | 1990-11-28 | 1998-11-17 | Sano Corporation | Transdermal administration of azapirones |
US5817331A (en) * | 1990-11-28 | 1998-10-06 | Sano Corporation | Transdermal administration of azapirones |
US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5137894A (en) * | 1991-12-05 | 1992-08-11 | New James S | 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides |
US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
US5496847A (en) * | 1993-10-14 | 1996-03-05 | Bristol-Myers Squibb Co. | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
US5391570A (en) * | 1993-10-14 | 1995-02-21 | Bristol-Myers Squibb | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
US5658941A (en) * | 1993-10-14 | 1997-08-19 | Bristol-Myers Squibb Company | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
EP0655449A1 (en) * | 1993-11-10 | 1995-05-31 | Jin Ro Limited | A process for preparing N-( 2-pyrimidyl) piperazinyl butyl imides |
US5538985A (en) * | 1994-01-27 | 1996-07-23 | Mitsui Toatsu Chemicals, Inc. | Pyrrolidinone derivatives |
US5521313A (en) * | 1994-05-05 | 1996-05-28 | Bristol-Myers Squibb Company | Process for preparing certain azapirones |
ES2082727A1 (es) * | 1994-09-01 | 1996-03-16 | Univ Madrid Complutense | Nuevos derivados de arilpiperazinas. |
WO1996006846A1 (es) * | 1994-09-01 | 1996-03-07 | Universidad Complutense De Madrid | Nuevos derivados de arilpiperazinas |
US5602128A (en) * | 1994-12-02 | 1997-02-11 | American Home Products Corporation | N-heterocycloalkyl carboxamides as serotonergic agents |
US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
ES2095811A1 (es) * | 1995-07-28 | 1997-02-16 | Univ Madrid Complutense | Nuevos derivados de arilpiperazinas. |
US6008222A (en) * | 1996-12-04 | 1999-12-28 | Bristol-Myers Squibb Company | Method for oral administration of buspirone and nefazodone |
US6228864B1 (en) | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
US6037360A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
US7049330B2 (en) | 1998-06-15 | 2006-05-23 | Wyeth | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6518272B2 (en) | 1998-06-15 | 2003-02-11 | Wyeth | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US20030139449A1 (en) * | 1998-06-15 | 2003-07-24 | Wyeth | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
WO2000006163A1 (en) * | 1998-07-30 | 2000-02-10 | Bristol-Myers Squibb Company | Improved method for treatment of sleep-related respiratory disorders |
US6313114B1 (en) | 1999-01-07 | 2001-11-06 | American Home Products Corp | 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]- amines |
US6306859B1 (en) | 1999-03-02 | 2001-10-23 | American Home Products Corporation | N-substituted imide derivatives with serotonergic activity |
US6566361B2 (en) | 1999-06-30 | 2003-05-20 | Laboratories, Upsa | Azapirone pain treatment |
US20030069251A1 (en) * | 1999-08-05 | 2003-04-10 | Yevich Joseph P. | Antianxiety composition |
US6150365A (en) * | 1999-08-05 | 2000-11-21 | Bristol-Myers Squibb Company | Anxiety method |
US20050137206A1 (en) * | 1999-08-05 | 2005-06-23 | Yevich Joseph P. | Method for treatment of anxiety and depression |
US6828324B2 (en) | 1999-11-12 | 2004-12-07 | Wyeth | Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT1A activity |
US6831084B1 (en) | 1999-11-12 | 2004-12-14 | Wyeth | Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity |
US7517904B2 (en) | 2000-09-19 | 2009-04-14 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20050272799A1 (en) * | 2000-09-19 | 2005-12-08 | Salvati Mark E | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20040067962A1 (en) * | 2000-11-29 | 2004-04-08 | Schaus John Mehnert | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof |
US6864262B2 (en) | 2000-11-29 | 2005-03-08 | Eli Lilly And Company | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof |
US20060223832A1 (en) * | 2001-06-20 | 2006-10-05 | Salvati Mark E | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US7470797B2 (en) | 2001-06-20 | 2008-12-30 | Bristol-Myers Squibb Company | Fused heterocyclic imido and amido compounds |
US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
US9849117B2 (en) | 2002-09-04 | 2017-12-26 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
US9567343B2 (en) | 2002-09-04 | 2017-02-14 | Novartis Ag | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists |
US7067518B2 (en) | 2002-09-05 | 2006-06-27 | Wyeth | Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents |
US20050107395A1 (en) * | 2002-09-05 | 2005-05-19 | Greenblatt Lynne P. | Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents |
US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
US20110034475A1 (en) * | 2004-06-18 | 2011-02-10 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
EP2336129A1 (en) | 2004-06-18 | 2011-06-22 | Novartis AG | 1-aza-bicyclo[3.3.1]nonanes |
US9475811B2 (en) | 2004-06-18 | 2016-10-25 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
EP2457911A1 (en) | 2004-07-14 | 2012-05-30 | Novartis AG | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. |
US9657010B2 (en) | 2004-07-14 | 2017-05-23 | Novartis Ag | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators |
EP2463278A1 (en) | 2005-04-11 | 2012-06-13 | Novartis AG | 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands |
EP2468732A1 (en) | 2005-04-11 | 2012-06-27 | Novartis AG | 1H-Quinazoline-2,4-diones |
EP2476671A1 (en) | 2005-04-11 | 2012-07-18 | Novartis AG | 1H-Quinazoline-2,4-diones |
WO2006108591A1 (en) | 2005-04-11 | 2006-10-19 | Novartis Ag | 1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands |
US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
EP2361914A1 (en) | 2005-12-16 | 2011-08-31 | Novartis AG | [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders. |
US20100184775A1 (en) * | 2005-12-16 | 2010-07-22 | Novartis Ag | Organic compounds |
US9206181B2 (en) | 2005-12-16 | 2015-12-08 | Novartis Ag | 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders |
EP2354141A1 (en) | 2005-12-16 | 2011-08-10 | Novartis AG | (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders. |
US20090023744A1 (en) * | 2007-06-18 | 2009-01-22 | The General Hospital Corporation | Combination therapy for depression |
US8735578B2 (en) | 2010-09-24 | 2014-05-27 | Aché Laboratórios Farmacêuticos S.A. | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors |
WO2012037634A1 (en) | 2010-09-24 | 2012-03-29 | Aché Laboratórios Farmacêuticos S.A. | Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors |
US9186359B2 (en) | 2010-10-15 | 2015-11-17 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
US10632116B2 (en) | 2010-10-15 | 2020-04-28 | Contera Pharma A/S | Combinations of serotonin receptor agonists for treatment of movement disorders |
US10561618B2 (en) | 2012-04-18 | 2020-02-18 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
US11975104B2 (en) | 2016-07-11 | 2024-05-07 | Contera Pharma A/S | Pulsatile drug delivery system for treating morning akinesia |
Also Published As
Publication number | Publication date |
---|---|
CH552607A (de) | 1974-08-15 |
MY7700151A (en) | 1977-12-31 |
NL7017031A (xx) | 1971-05-26 |
BE759371A (fr) | 1971-05-24 |
KE2691A (en) | 1977-03-04 |
US3907801A (en) | 1975-09-23 |
FR2073406B1 (xx) | 1974-10-11 |
DK141753B (da) | 1980-06-09 |
FR2073406A1 (xx) | 1971-10-01 |
GB1332194A (en) | 1973-10-03 |
ES8505251A3 (es) | 1985-05-16 |
DK141753C (xx) | 1980-11-24 |
CH552608A (de) | 1974-08-15 |
CY886A (en) | 1977-03-18 |
ZA707826B (en) | 1971-07-28 |
DE2057845A1 (de) | 1971-06-09 |
ES530335A0 (es) | 1985-05-16 |
HK6177A (en) | 1977-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3717634A (en) | N-(heteroarcyclic)piperazinylalkyl-azaspiroalkanediones | |
US3976776A (en) | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones | |
EP0563345B1 (en) | Novel 4-arylpiperazines and 4-arylpiperidines | |
CA1184915A (en) | N-¬.alpha.-(4-R-1-PIPERAZINYL)-ALKYL|BICYCLO ¬2.2.1|HEPT-5-ENE-2,3-DI-EXO-CARBOXIMIDE | |
US4059621A (en) | Substituted benzamido propanolamines | |
US3511841A (en) | 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines | |
US6175015B1 (en) | Fused indolecarboxamides: dopamine receptor subtype specific ligands | |
JPH0587506B2 (xx) | ||
HU204816B (en) | Process for producing indazole-3-carboxylic acid derivatives and pharmaceutical compositions comprising same | |
EP0309544B1 (en) | Psychotropic bicyclic imides | |
DE69321609T2 (de) | Piperazinderivate | |
US3367936A (en) | 4-(piperazinoalkyl)-pyrazoles | |
EP0784055A1 (en) | Pyrimidinylpyrazole derivative | |
EP0599240B1 (en) | Indole-7-carboxamide derivatives as analgesics | |
US4379160A (en) | Carbazole compounds and medicinal use thereof | |
US3270014A (en) | 1, 2-dihydro-1-hydroxy-1, 3, 5-triazines | |
FI77456C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-/2-/4-(2-metoxifenyl) -1-piperazinyl/etyl/-2,4-(1h,3h)-kinazolindionderivat. | |
DE19742014A1 (de) | Neue Tetracyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
US3647794A (en) | S-triazine compounds | |
EP0660822B1 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents | |
DK149133B (da) | Analogifremgangsmaade til fremstilling af 2-(4-(diphenylmethylen)- l-piperidinyl)- eddikesyrer eller farmaceutisk acceptable salte heraf | |
EP0060610A1 (en) | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | |
US3590043A (en) | Condensed isoindolone derivatives | |
PT92234B (pt) | Processo para a preparacao de 1,2,3,4-tetraidro-1,9-acridinodiaminas | |
US3821225A (en) | Pyridyl piperazines |